CoChat

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies

Open access
Phillip, Moshe, Mathieu, Chantal, Lind, Marcus, Araki, Eiichi, di Bartolo, Paolo, Bergenstal, Richard, Heller, Simon, Hansen, Lars, Scheerer, Markus Florian, Thoren, Fredrik, Arya, Niki, Xu, John, Iqbal, Nayyar, Dandona, Paresh, DEPICT‐1 and DEPICT‐2 Investigators · 2021 · Diabetes, Obesity and Metabolism
Cited by 41

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Aim: To evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients with type 1 diabetes (T1D). Materials and Methods: DEPICT‐1 and ‐2 were randomized, double‐blind, parallel‐group, 24‐week studies, with 28‐week extension periods. Adults with T1D and HbA1c 7.5%‐10.5% were randomized (1:1:1) to receive dapagliflozin 5 mg, 10 mg or placebo. The short‐ and long‐term efficacy and safety of dapagliflozin were examined in an exploratory pooled analysis of both studies. Results: Efficacy analyses included 530, 529 and 532 and safety analysis included 548, 566 and 532 patients in the dapagliflozin 5 mg, 10 mg and placebo groups, respectively. Baseline characteristics were similar between treatment groups. At week 24, reductions were seen with dapagliflozin 5 and 10 mg compared with placebo in HbA1c (−0.40%, −0.43% vs. 0.00%) and body weight (−2.45, −2.91 vs. 0.11 kg). HbA1c and body weight reductions versus placebo were also seen after 52 weeks of treatment. There was no imbalance in occurrence of severe hypoglycaemic events between groups. The proportion of patients experiencing definite diabetic ketoacidosis (DKA) was higher with dapagliflozin 5 mg (4.0%) and 10 mg (3.5%) compared with placebo (1.1%) over 52 weeks; most events were of mild or moderate severity, and all resolved with treatment. Conclusions: Over 52 weeks, dapagliflozin provided glycaemic and weight benefits, with no increased frequency of severe hypoglycaemia compared with placebo. More DKA events were reported with dapagliflozin than placebo, highlighting the importance of appropriate patient selection, education and risk‐mitigation strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14248

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

Metadata

Authors
Phillip, M., Mathieu, C., Lind, M., Araki, E., di Bartolo, P., Bergenstal, R., Heller, S., Hansen, L., Scheerer, M. F., Thoren, F., Arya, N., Xu, J., Iqbal, N., Dandona, P., & DEPICT‐1 and DEPICT‐2 Investigators
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2020-11-24
Volume
23
Issue
2
Pages
549-560
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3096958617
Cited by
41
References
18
FWCI
3.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.